Heterogeneous ligand-mediated Ca++ responses at wt and mutant α2A-adrenoceptors suggest multiple ligand activation binding sites at the α2A-adrenoceptor

被引:14
作者
Pauwels, PJ [1 ]
Colpaert, FC [1 ]
机构
[1] Ctr Rech Pierre Fabre, Dept Cellular & Mol Biol, F-81106 Castres, France
关键词
recombinant human alpha(2A) AR; mutagenesis; Ca++ response; intrinsic ligand activity; differential signalling;
D O I
10.1016/S0028-3908(00)00040-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Ligand:receptor interactions were analysed at wild-type, Asp(79)Asn and Th(373)Lys alpha(2A) AR by measuring Ca++ responses in the co-presence of a G(alpha 15) protein in CHO-K1 cells. (-)-Adrenaline displayed a time-dependent Ca++ response with the following magnitude: wt alpha(2A) AR>Thr(373)Lys alpha(2A) AR>Asp(79)Asn alpha(2A) AR. The maximal amplitude of activation by d-medetomidine and clonidine versus that of (-)-adrenaline was not affected by the Asp(79)Asn mutation, whereas it was significantly lower for both UK 14304 (-42%) and oxymetazoline (-35%). BHT 920 induced a higher Ca++ response (+19%) at the Asp79Asn alpha(2A) AR. Some (atipamezole>BRL 44408=idazoxan similar or equal to SKF 86466>dexefaroxan) but not all (RX 811059 and RS 15385) of the putative alpha(2)AR antagonists tested also displayed partial agonist properties at the Asp(79)Asn alpha(2A) AR. At the Thr(373)Lys alpha(2A) AR, high-efficacy responses were produced by each of the agonists, whereas the putative antagonists showed the following rank order of maximal responses: BRL 44408 >SKF 86466>Btipamezole-idazoxan>dexefaroxan. The observed heterogeneity of Ca++ responses produced by differ ent ligands at wt and mutant alpha(2A) AR may be explained by assuming the existence of multiple ligand activation binding sites at the alpha(2A) AR. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2101 / 2111
页数:11
相关论文
共 24 条
[1]   Abnormal regulation of the sympathetic nervous system in α2A-adrenergic receptor knockout mice [J].
Altman, JD ;
Trendelenburg, AU ;
Macmillan, L ;
Bernstein, D ;
Limbird, L ;
Starke, K ;
Kobilka, BK ;
Hein, L .
MOLECULAR PHARMACOLOGY, 1999, 56 (01) :154-161
[2]  
ARRIESS CN, 1997, BRIT J PHARMACOL, V122, P191
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]  
Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924
[5]  
COLQUHOUN D, 1973, DRUG RECEPTORS, P149, DOI DOI 10.1007/978-1-349-00910-7_11
[6]   REGIONS OF THE ALPHA-1-ADRENERGIC RECEPTOR INVOLVED IN COUPLING TO PHOSPHATIDYLINOSITOL HYDROLYSIS AND ENHANCED SENSITIVITY OF BIOLOGICAL FUNCTION [J].
COTECCHIA, S ;
EXUM, S ;
CARON, MG ;
LEFKOWITZ, RJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (08) :2896-2900
[7]  
EASON MG, 1994, MOL PHARMACOL, V45, P696
[8]   Adrenergic receptors - From molecular structure to in vivo function [J].
Hein, L ;
Kobilka, BK .
TRENDS IN CARDIOVASCULAR MEDICINE, 1997, 7 (05) :137-145
[9]   Ligand efficacy and potency at recombinant α2 adrenergic receptors -: Agonist-mediated [35S]GTPγS binding [J].
Jasper, JR ;
Lesnick, JD ;
Chang, LK ;
Yamanishi, SS ;
Chang, TK ;
Hsu, SAO ;
Daunt, DA ;
Bonhaus, DW ;
Eglen, RM .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (07) :1035-1043
[10]  
Kukkonen JP, 1998, J PHARMACOL EXP THER, V287, P667